These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23347624)

  • 1. Drotrecogin alfa (activated) in severe sepsis.
    Poole D; Rossi C; Addis A; Livigni S; Bertolini G
    Lancet Infect Dis; 2013 Feb; 13(2):107-8. PubMed ID: 23347624
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) in severe sepsis.
    Gayat E; Lemasle L; Payen D
    Lancet Infect Dis; 2013 Feb; 13(2):109-10. PubMed ID: 23347627
    [No Abstract]   [Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) in severe sepsis.
    Janes JM; Vangerow B; Costigan TM; Macias WL
    Lancet Infect Dis; 2013 Feb; 13(2):108-9. PubMed ID: 23347626
    [No Abstract]   [Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) in severe sepsis.
    Marik PE
    Lancet Infect Dis; 2013 Feb; 13(2):107. PubMed ID: 23347625
    [No Abstract]   [Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in severe sepsis--authors' reply.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2013 Feb; 13(2):110-1. PubMed ID: 23347628
    [No Abstract]   [Full Text] [Related]  

  • 6. The rise and fall of drotrecogin alfa (activated).
    Vincent JL
    Lancet Infect Dis; 2012 Sep; 12(9):649-51. PubMed ID: 22809884
    [No Abstract]   [Full Text] [Related]  

  • 7. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
    Laterre PF; Wittebole X
    Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated).
    Urban TM; Mitchell GA; Wellborn-Kim JJ; Terneus WF; Callahan CM; Mendes J; Webber SL
    Am J Health Syst Pharm; 2010 Jul; 67(14):1174-7. PubMed ID: 20592322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis.
    Olsen KM; Martin SJ
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):196S-205S. PubMed ID: 12492226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current issues regarding the use of drotrecogin alfa (activated).
    Hassan E; Mann HJ
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):206S-215S. PubMed ID: 12492227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 17. The safety profile of drotrecogin alfa (activated).
    Fumagalli R; Mignini MA
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S6. PubMed ID: 18269693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 19. Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies.
    Cohen H; Welage LS
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):223S-235S. PubMed ID: 12492229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.